Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Overview of attention for article published in OncoTargets and therapy, November 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 1 X user
reddit: 1 Redditor

video: 1 YouTube creator

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 44 Mendeley

Summary X Reddit YouTube Dimensions citations

So far, Dimensions has found 21 publications that cite this research output.

21

The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.

The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA

Article in Heliyon (April 2024)

QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment

Article in Quality of Life Research (December 2023)

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need

Article in International Journal of Molecular Sciences (May 2023)